Affordable Access

Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer

Libertas Academica
Publication Date
  • Clinical Medicine Insights: Oncology
  • Volume: 2011
  • Issue: 5
  • Biology
  • Medicine
  • Pharmacology


Clinical Medicine Insights: Oncology 2011:5 223–234 doi: 10.4137/CMO.S5964 This article is available from © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. Open Access Full open access to this and thousands of other papers at Clinical Medicine Insights: Oncology E x p E r T r E v I E w Clinical Medicine Insights: Oncology 2011:5 223 current and emerging pharmacotherapies for the Treatment of Relapsed small cell Lung cancer Binu S. Nair, MD, vipul Bhanderi, MD and Syed H. Jafri, MD Department of Medicine, Feist-weiller Cancer Center, Louisiana State University, Shreveport, LA 71103, USA. Corresponding author email: [email protected] Abstract: Small cell lung cancer (SCLC) is a very aggressive cancer with poor outcome if left untreated, but it is also one of the most chemotherapy responsive cancers. Overall it has a very poor prognosis especially if it is chemotherapy resistant to first line treatment. Second line chemotherapy has not been very beneficial in SCLC as opposed to breast cancer and lymphoma. In the last few years topotecan is the only drug that has been approved by the food and drug administration (FDA) for the second line treatment of SCLC but in Japan another drug, amrubicin is approved. There are many combinations of different chemotherapies available in moderate to high intensity, in this difficult to treat patient to overcome the chemo resistance, but many of these studies are small or phase II trials. In this article we have reviewed single agent and multidrug regimens that were studied in both chemo sensitive and refractory setting, including the most recent clinical trials. Keywords: small cell lung cancer, relapsed, refractory, topotecan, amrubicin Nair et al 224 Clinical Medicine Insights: Oncology 2011:5 Introduction and Background Lung

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times